Penumbra, Inc. PEN
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About PEN
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Penumbra, Inc. is a U.S.-based medical device company focused on developing and commercializing technologies for the diagnosis and treatment of vascular and neurological conditions. The company primarily operates in the interventional healthcare and medical technology industries, with a concentration on neurovascular and peripheral vascular therapies. Penumbra’s products are widely used in minimally invasive procedures intended to treat ischemic stroke, venous thromboembolism, pulmonary embolism, and other vascular disorders. The company also operates in healthcare immersive technologies through its rehabilitation and performance-focused digital products.
The company’s principal revenue drivers include thrombectomy systems, aspiration catheters, embolization devices, access systems, and associated consumables used in neuro and peripheral interventions. Key customer segments include hospitals, stroke centers, interventional radiologists, neurosurgeons, neurologists, and vascular specialists. Penumbra is recognized for its emphasis on aspiration-based thrombectomy technology and physician-focused device innovation. Founded in 2004 by Adam Elsesser, the company initially focused on stroke intervention technologies and expanded into broader vascular and thrombectomy markets through internal development and selective acquisitions. Over time, Penumbra broadened its portfolio into computer-assisted rehabilitation and immersive healthcare technologies.
Business Operations
Penumbra generates revenue primarily through sales of devices across its Thrombectomy, Embolization and Access, and healthcare technology product categories. Its neurovascular business includes products designed for acute ischemic stroke treatment and cerebral aneurysm management, while its peripheral vascular portfolio addresses pulmonary embolism, deep vein thrombosis, and related circulatory conditions. Revenue is largely derived from recurring hospital usage of disposable devices and procedure-driven demand. The company reports significant sales activity in the United States while continuing to expand internationally across Europe, Asia-Pacific, Latin America, and select Middle Eastern markets.
The company controls a portfolio of proprietary aspiration thrombectomy technologies, catheter systems, software-enabled rehabilitation platforms, and physician workflow tools. Penumbra has developed integrated systems combining aspiration pumps, engineered catheters, and clot extraction technologies. Important subsidiaries and operating entities include Penumbra Europe GmbH and other regional commercial organizations supporting international distribution and regulatory operations. Penumbra has also entered collaborations with healthcare providers, distributors, and technology partners to expand procedural adoption and digital rehabilitation offerings.
Strategic Position & Investments
Penumbra’s strategic direction centers on expanding adoption of minimally invasive thrombectomy procedures, increasing penetration in underdiagnosed vascular conditions, and investing in next-generation medical technologies. The company has focused heavily on physician education, clinical evidence generation, and product iteration to strengthen its competitive position against larger medical device manufacturers operating in neurovascular and peripheral intervention markets. Growth initiatives include expansion of indication-specific aspiration systems, broader international commercialization, and development of advanced procedural technologies.
The company has made investments in immersive healthcare technologies and rehabilitation systems through its REAL System platform, which combines virtual reality and motion-tracking tools for rehabilitation and physical performance applications. Penumbra has also pursued acquisitions and portfolio expansion initiatives to strengthen its thrombectomy and vascular intervention capabilities. Its investment priorities have included manufacturing scale, research and development infrastructure, and expanded clinical trial activity supporting regulatory approvals and physician adoption globally.
Geographic Footprint
Penumbra is headquartered in Alameda, California, and maintains commercial and operational activities across North America, Europe, Asia-Pacific, and parts of Latin America and the Middle East. The United States remains its largest market by revenue, supported by widespread adoption of stroke intervention and thrombectomy procedures at comprehensive stroke centers and major hospital systems. Internationally, the company continues to expand through direct sales organizations and distributor partnerships.
The company’s products are marketed in more than 100 countries, with meaningful commercial operations in countries including Germany, France, the United Kingdom, Japan, China, Canada, and Australia. Penumbra’s global footprint is supported by regional regulatory approvals, physician training programs, and localized sales infrastructure designed to increase adoption of advanced thrombectomy and neurovascular technologies.
Leadership & Governance
Penumbra was founded by Adam Elsesser, who has remained central to the company’s strategic and operational leadership since inception. The company’s leadership philosophy has emphasized clinical innovation, physician collaboration, and long-term investment in minimally invasive treatment technologies. Public filings and investor communications indicate that management prioritizes sustained research and development spending, operational scalability, and evidence-based commercialization.
Key executives include:
- Adam Elsesser – Chairman of the Board and Chief Executive Officer
- Maggie Yuen – Chief Financial Officer
- Harpreet Grewal, M.D. – Executive Vice President and General Manager, Thrombectomy
- Dan Schoenberg – Executive Vice President and Chief Innovation Officer
- Mark Loboda – Executive Vice President and President, North America Commercial Operations
The company operates under a publicly traded governance structure with oversight from its board of directors and adherence to U.S. public company reporting standards, including disclosures contained in SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q.